This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) focuses on advances in high throughput enzymatic DNA synthesis technologies which are being adopted across multiple lifescience and healthcare applications. The applications of gene circuits in drug discovery and therapeutics development has also been captured with innovations highlighting the use of engineered stem cells for drug discovery, and programmable cell and gene therapies amongst others. Engineered synthetic cells, microbes for antibiotic production and cell-free biosensors for environment applications are some of the other synbio related innovations covered in this issue.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Table of Contents
Innovations in Synthetic Biology Enablers and Applications, Microbiome Therapeutics, Exosome-Based Drug Delivery
- Surface Display of RNA Nanoparticles on Exosomes for Targeted siRNA Delivery
- ExonanoRNA’s Value Proposition
- ExonanoRNA - Investor Dashboard
- Optically Reversible Protein Encapsulation in Exosomes to Control Loading and Target Inaccessible Proteins
- Value Proposition of ILIAS
- ILIAS - Investor Dashboard
- Automated, Scalable Manufacturing for In Silico Engineered Targeted Exosomes
- Mantra Bio’s Value Proposition
- Mantra Bio - Investor Dashboard
- Pharmacological Chaperones and Protein Stabilizing Therapeutics Targeting Protein Misfolding Disorders
- Value Proposition of Protego Biopharma
- Protego Biopharma- Investor Dashboard
- Improved Glycoprotein Purification And Analysis Using Recombinant Prokaryotic Lectins
- GlycoSeLect’s Value Proposition
- GlycoSeLect - Investor Dashboard
- Actinomycete Engineering Technology for Antibiotic Development with Required Bioactivity
- Fermalogic’s Value Proposition
- Fermalogic - Investor Dashboard
- Tumor Microenvironment Sensing Targeted CAR-T Cell Therapies With Reduced Side Effects
- Refuge Biotechnologies’ Value Proposition
- Refuge Biotechnologies - Investor Dashboard
- Engineered Synthetic Cells with Embedded Circuits to Find Utility Across Biomedical Applications
- Synlife’s Value Proposition
- Synlife - Investor Dashboard
- Enzymatic De novo Synthesis and Gene Assembly Technology for Accurate Synthesis of complex DNA
- Enzymatic DNA Synthesis with High Accuracy
- Camena Bioscience - Investor Dashboard
- Electrochemical Array Evaluating the Dysbiosis of Metabolites to Restore Gut Health
- Premium-grade Individualized Supplements from Ixcela
- Ixcela - Investor Dashboard
- Gene Circuit-guided Precise Antimicrobials and In-vivo Editing of Microbiomes
- Eligo Biosciences Precise Anti Bacterial Platform
- Eligo Bioscience - Investor Dashboard
- Portable Cell-Free Biosensors for Rapid Detection of Water Contaminants
- 3D-Printed Handheld Device for Water Quality Testing
- Stemloop, Inc. - Investor Dashboard
- Bacteriophage-based Skin Solutions Targeting Acne and Skin Irritation
- Effective and Targeted Serum for Skincare
- Ellis Day Skin Science - Investor Dashboard
- Lab-on-Chip Based Portable DNA and Protein Synthesis Platform
- Accessing Biomolecules With Desktop Bioprinter
- Nuclera Nucleics Ltd - Investor Dashboard
- Accurate and Cost-efficient Ultra-long Synthetic DNA Synthesis for Multiple applications
- Molecular Assemblies - Investor Dashboard
- Automating Long and Ultra-long DNA Printing Process
- Shelf-stable Precise Synthetic Cells with for Drug Discovery and Diagnostics Applications
- Calibration and Standardization Technology from Slingshot Biosciences
- Slingshot Biosciences - Investor Dashboard
- Scalable and Precise Cell Reprogramming Platform Using Gene Circuits for Drug Discovery and Disease Pathogenesis Modeling
- Value Proposition of bit.bio
- bit.bio- Investor Dashboard
- Promoter-Free Gene Circuits Identifying and Killing Tumor Cells through Targeted Antibodies
- Value Proposition of Southern Medical University
- Key Contacts
- Appendix
- Criteria for Rating of Innovations--Explanation
- Legal Disclaimer
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- bit.bio
- Camena Bioscience
- Eligo Bioscience
- Ellis Day Skin Science
- ExonanoRNA
- Fermalogic
- GlycoSeLect
- ILIAS
- Ixcela
- Mantra Bio
- Molecular Assemblies
- Nuclera Nucleics Ltd
- Protego Biopharma
- Refuge Biotechnologies
- Slingshot Biosciences
- Stemloop, Inc.
- Synlife
